Rare case of de novo EGFR L718V mutation-positive non-small cell lung cancer successfully treated with afatinib

Rare case of de novo EGFR L718V mutation-positive non-small cell lung cancer successfully treated with afatinib

Since the FLAURA trial, epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) has generally been treated with osimertinib as a first-line therapy. However, there is still insufficient data on the therapeutic efficacy of EGFR-tyrosine kinase inhibitors in NSCLC...

Full description

Bibliographic Details
Main Authors: Takanori Ito, Kohei Fujita, Zentaro Saito, Takuma Imakita, Issei Oi, Osamu Kanai, Hiromasa Tachibana, Tadashi Mio
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:Current Problems in Cancer: Case Reports
Subjects:
EGFR mutation
L718V
Afatinib
Osimertinib
Resistance
Lung cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2666621923000133

Internet

http://www.sciencedirect.com/science/article/pii/S2666621923000133

Similar Items